Recruiting
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
ClinicalTrials.gov IDNCT07241546
PhasePHASE2
Enrollment36
SponsorArrowhead Pharmaceuticals
Age18 Years
SexALL
Conditions studied
Asthma
About this study
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
Interventions
- Drug: ARO-RAGE — Inhalation of nebulized solution
- Drug: Placebo — Calculated volume to match active treatment by inhalation of nebulized solution
Primary outcomes
- Change from Baseline Over Time in Maximum Area of Reactance (Baseline through Day 58)
Eligibility information
Inclusion Criteria:
* Clinically stable, mild atopic asthma (FEV1 ≥70% predicted)
* Established allergy confirmed by positive skin prick test at screening
* Willing and able to perform lung function tests and other study-related procedures
* Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later
Exclusion Criteria:
* Concomitant diagnosis of a clinically important pulmonary disease other than asthma
* Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma
* History or current medical condition contraindicating methacholine challenge
Note: Additional inclusion/exclusion criteria may apply per protocol.
Study locations
- Research Site 1, Vancouver, British Columbia Canada
- Research Site 2, Calgary, T2N 4N1 Canada
- Research Site 3, Edmonton, T6G 2G3 Canada
- Research Site 5, Hamilton, L8N 3Z5 Canada
- Research Site 4, Saskatoon, S7M 2W2 Canada
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.